WallStreetZenWallStreetZen

NASDAQ: MRKR
Marker Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MRKR

Based on 1 analyst offering 12 month price targets for Marker Therapeutics Inc

Min Forecast
$10.00+599.3%
Avg Forecast
$10.00+599.3%
Max Forecast
$10.00+599.3%

Should I buy or sell MRKR stock?

Based on 1 analyst offering ratings for Marker Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MRKR stock forecasts and price targets.

MRKR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-08

1 of 1

Forecast return on equity

Is MRKR forecast to generate an efficient return?

Company
179.21%
Industry
74.01%
Market
170.14%
MRKR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MRKR forecast to generate an efficient return on assets?

Company
157.84%
Industry
29.14%
MRKR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MRKR earnings per share forecast

What is MRKR's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.01
Avg 2 year Forecast
-$1.04
Avg 3 year Forecast
$0.50

MRKR revenue forecast

What is MRKR's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$2.7M-22.49%
Avg 2 year Forecast
$28.5M+703.2%
Avg 3 year Forecast
$125.6M+3,440.22%
MRKR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MRKR revenue growth forecast

How is MRKR forecast to perform vs Biotechnology companies and vs the US market?

Company
217.65%
Industry
33.61%
Market
14.12%
MRKR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MRKR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MRKR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MRKR$1.43$10.00+599.30%Buy
LGVN$0.76$8.00+959.60%Buy
ALLR$1.54$9.75+533.12%Buy
PLRZ$15.18N/AN/A
CELU$0.79N/AN/A
View Top Biotech Stocks

Marker Therapeutics Stock Forecast FAQ

Is Marker Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MRKR) stock is to Buy MRKR stock.

Out of 1 analyst, 0 (0%) are recommending MRKR as a Strong Buy, 1 (100%) are recommending MRKR as a Buy, 0 (0%) are recommending MRKR as a Hold, 0 (0%) are recommending MRKR as a Sell, and 0 (0%) are recommending MRKR as a Strong Sell.

If you're new to stock investing, here's how to buy Marker Therapeutics stock.

What is MRKR's earnings growth forecast for 2026-2028?

(NASDAQ: MRKR) Marker Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Marker Therapeutics's earnings in 2026 is -$12,163,620.On average, 5 Wall Street analysts forecast MRKR's earnings for 2026 to be -$16,893,212, with the lowest MRKR earnings forecast at -$24,999,687, and the highest MRKR earnings forecast at -$10,679,138. On average, 5 Wall Street analysts forecast MRKR's earnings for 2027 to be -$17,290,033, with the lowest MRKR earnings forecast at -$24,672,893, and the highest MRKR earnings forecast at -$3,326,289.

In 2028, MRKR is forecast to generate $8,276,540 in earnings, with the lowest earnings forecast at -$16,829,854 and the highest earnings forecast at $25,209,768.

What is MRKR's revenue growth forecast for 2026-2028?

(NASDAQ: MRKR) Marker Therapeutics's forecast annual revenue growth rate of 217.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.12%.

Marker Therapeutics's revenue in 2026 is $3,546,669.On average, 5 Wall Street analysts forecast MRKR's revenue for 2026 to be $45,834,426, with the lowest MRKR revenue forecast at $0, and the highest MRKR revenue forecast at $101,272,573. On average, 5 Wall Street analysts forecast MRKR's revenue for 2027 to be $474,967,369, with the lowest MRKR revenue forecast at $375,812,283, and the highest MRKR revenue forecast at $575,222,882.

In 2028, MRKR is forecast to generate $2,093,477,826 in revenue, with the lowest revenue forecast at $1,634,366,601 and the highest revenue forecast at $2,558,991,532.

What is MRKR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MRKR) forecast ROA is 157.84%, which is higher than the forecast US Biotechnology industry average of 29.14%.

What is MRKR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MRKR price target, the average MRKR price target is $10.00, with the highest MRKR stock price forecast at $10.00 and the lowest MRKR stock price forecast at $10.00.

The Wall Street analyst predicted that Marker Therapeutics's share price could reach $10.00 by Dec 8, 2026. The average Marker Therapeutics stock price prediction forecasts a potential upside of 599.3% from the current MRKR share price of $1.43.

What is MRKR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MRKR) Marker Therapeutics's current Earnings Per Share (EPS) is -$0.79. On average, analysts forecast that MRKR's EPS will be -$1.01 for 2026, with the lowest EPS forecast at -$1.50, and the highest EPS forecast at -$0.64. On average, analysts forecast that MRKR's EPS will be -$1.04 for 2027, with the lowest EPS forecast at -$1.48, and the highest EPS forecast at -$0.20. In 2028, MRKR's EPS is forecast to hit $0.50 (min: -$1.01, max: $1.51).

What is MRKR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MRKR) forecast ROE is 179.21%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.